{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05865301",
            "orgStudyIdInfo": {
                "id": "IRB-70021"
            },
            "secondaryIdInfos": [
                {
                    "id": "Gift Funding",
                    "type": "OTHER",
                    "domain": "Bass Center Leukemia Pilot Grant"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy",
            "officialTitle": "Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "outcomes-in-pediatric-and-young-adult-b-cell-malignancies-after-commercially-available-immunotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-01",
            "studyFirstSubmitQcDate": "2023-05-09",
            "studyFirstPostDateStruct": {
                "date": "2023-05-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Bass Center Leukemia Pilot Grant",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Pediatric Oncology Experimental Therapeutics Investigators' Consort",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin."
        },
        "conditionsModule": {
            "conditions": [
                "Lymphoid Leukemia"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "OTHER"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A (Retrospective data)",
                    "description": "Participants who have undergone standard of care tisagenlecleucel therapy, Participants will received a questionnaire study using patient reported outcomes.",
                    "interventionNames": [
                        "Other: Questionnaire for patients receiving therapy"
                    ]
                },
                {
                    "label": "Arm B (Prospective data)",
                    "description": "Patients enrolled in ARM B will be asked to participate in the biological sample collection. Participants will received a questionnaire",
                    "interventionNames": [
                        "Other: Questionnaire for patients receiving therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Questionnaire for patients receiving therapy",
                    "description": "Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.",
                    "armGroupLabels": [
                        "Arm A (Retrospective data)",
                        "Arm B (Prospective data)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "WECARE-Survey",
                    "description": "Participant will take part in a one-time questionnaire to address CAR specific questions.\n\nWECARE survey, consists of questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language)",
                    "timeFrame": "at baseline"
                },
                {
                    "measure": "Retrospective WECARE Survey",
                    "description": "Surveys will be administered at a single time point post-CAR",
                    "timeFrame": "up to 12 months post infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "overall survival (OS)",
                    "description": "Overall survival was the duration from the start of study treatment to death.",
                    "timeFrame": "at baseline up to 12 months post infusion"
                },
                {
                    "measure": "event-free-survival (EFS)",
                    "description": "probability of recurrence or progression of in patients",
                    "timeFrame": "at baseline up to 12 months post infusion"
                },
                {
                    "measure": "duration of remission (DOR)",
                    "timeFrame": "at baseline up to 12 months post infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria (Arm A)\n\n\\* Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma\n\nWho either:\n\n* Experienced refractory or relapsed disease, treated with standard chemotherapy, without immunotherapy treatment.\n\nOR\n\n* Previously undergone standard of care immunotherapy with FDA approved therapies, such as Kymriah\u2122 (CTL019, tisagenlecleucel), blinatumomab or\n\n  * Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age.\n\nInclusion Criteria (Arm B)\n\n* Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma\n* Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age\n* Patients who are either:\n\n  * Undergoing evaluation for leukapheresis for planned standard of care tisagenlecleucel therapy, or planned for therapy with blinatumomab or inotuzumab. (Patients who received prior tisagenlecleucel, blinatumomab or inotuzumab on an established clinical trial and are now scheduled for commercial CAR, blinatumomab or inotuzumab therapy are also eligible) Or\n  * Experienced refractory or relapsed B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma\n* Ability to give informed consent. All subjects \u2265 18 years of age must be able to give informed consent or have legal authorized representative (LAR) (i.e. parent or guardian) to consent, if not in capacity to give consent independently. For subjects \\<18 years old their LAR must give informed consent. Pediatric subjects will be included in age appropriate discussion and written assent will be obtained for those \\> 7 years of age, when appropriate, according to institutional procedures.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "26 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Both Arm A and Arm B, includes retrospective and prospective data collection for patients experiencing refractory disease or first relapse, who have not received immunotherapy and are not yet being considered for immunotherapy. Retrospective data collection will parallel Arm A and patients will not require consent or assent. Prospective data collection will parallel Arm B and will require patient consent and assent as relevant",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Khanh Nguyen",
                    "role": "CONTACT",
                    "phone": "(650) 721-2372",
                    "email": "khanhpn@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Liora Schultz, M.D",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Khanh Nguyen",
                            "role": "CONTACT",
                            "phone": "650-721-2372",
                            "email": "khanhpn@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "asFound": "Lymphoid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M163159",
                    "name": "Tisagenlecleucel",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}